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Abstract
Objectives The present systematic review compared the effec-
tiveness of soft tissue substitutes (STSs) and autogenous free
gingival grafts (FGGs) in non-root-coverage procedures to
increase keratinized tissue (KT) width around teeth.
Materials and methods Included studies fulfilled the follow-
ing main eligibility criteria: (a) preclinical in vivo or human
controlled trials using FGG as control, (b) non-root-coverage
procedures, and (c) assessment of KT width. Meta-analysis
was performed on the gain in KT width (primary outcome
variable) and several secondary variables.
Results Eight human trials with short observation time evalu-
ating five different STSs were identified. FGG yielded consis-
tently significantly (p < 0.001) larger increase in KT width
irrespective whether the comparison regarded an acellular ma-
trix or a tissue-engineered STS. Further, FGG yielded consis-
tently ≥2 mm KTwidth postoperatively, while use of STS did
not, in the few studies reporting on this outcome. On the other
hand, STSs resulted in significantly better aesthetic outcomes
and received greater patient preference (p < 0.001).
Conclusions Based on relatively limited evidence, in non-
root-coverage procedures, FGG (1) resulted consistently in
significantly larger increase in KT width compared to STS
and (2) yielded consistently ≥2 mmKTwidth postoperatively,
while STSs did not. STSs yielded significantly better aesthetic
outcomes, received greater patient preference, and appeared
safe.
Clinical relevance Larger and more predictable increase in
KTwidth is achieved with FGG, but STSs may be considered
when aesthetics is important. Clinical studies reporting rele-
vant posttreatment outcomes, e.g., postop KT width ≥2 mm,
on the long-term (>6 months) are warranted.
Keywords Attached gingiva . Keratinized tissue .
Meta-analysis . Randomized controlled trials . Soft tissue
augmentation . Systematic review
Background
It is currently accepted that a minimum width of keratinized
tissue (KT) around teeth is not necessary to maintain peri-
odontal health and/or prevent gingival recession development,
when adequate plaque control is performed. However, if
plaque control is inadequate and/or a submarginal restoration
is necessary, a minimum of 2 mm of KT (i.e., ca. 1 mm of free
gingiva and 1 mm attached gingiva (AG)) is recommended
[1]; hence, in such patients lacking 2 mmKTwidth, soft tissue
augmentation procedures should be considered (for review,
see Scheyer et al. [2]).
Various non-root coverage procedures aiming to increase
the width of KT in terms of apico-coronal dimension have
been proposed through the years. These include various flap
designs, usually in combination with autogenous soft tissue
grafting. In a review performed a few years ago by Thoma
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et al. [3] the apically positioned flap (APF) in combination
with an autogenous free gingival graft (FGG) from the palate
was found to result in significantly higher increase in KT
width compared to APF alone and marginally significant
higher increase compared to APF in combination with a soft
tissue substitute (STS). Grafting with FGG, however, has
some major disadvantages: (1) need for second surgical site
contributing to patient morbidity, (2) occasionally relatively
limited supply, (3) some risk for surgical complications (i.e.,
intraoperative violation of the greater palatine vessels and
nerves or a strong postoperative bleeding), and (4) often an
unsatisfactory aesthetic outcome due to a “patch-like” appear-
ance with significant color mismatch to the neighboring tis-
sue. Thus, STSs appear as an attractive alternative to FGG.
Indeed, new STS products have appeared in the market
since the review mentioned previously [3], and although all
alternatives to a FGG have been summarized in the last AAP
workshop [1], no recent meta-analysis is available on this
specific comparison. Hence, the aim of the present study
was to conduct a systematic review and meta-analysis to an-
swer the following focused question, according to the popu-
lation, intervention, comparison, outcomes, and study design
criteria [4]: “In animal or human trials, are STSs equally effi-
cacious as autogenous palatal soft tissue grafts (FGG or con-
nective tissue grafts (CTG)) in non-root-coverage procedures
aiming to increase the apico-coronal width of KTaround teeth,
including aesthetic and patient-reported outcome measures
(PROMs)?”
Materials and methods
Protocol and eligibility criteria
The present systematic review followed the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA; Appendix 1; [5, 6]). The following inclusion
criteria were applied during literature search on original stud-
ies: (a) English or German language, (b) full text available, (c)
preclinical in vivo trials or (d) human controlled or random-
ized controlled clinical trials (RCTs) with ≥5 patients and ≥3-
month follow-up, (e) non-root coverage procedures, and (f)
preoperative and postoperative assessment of the KT width.
Studies were excluded if not all inclusion criteria were met
and if they regarded in vitro studies or augmentation of KT in
fully edentulous patients or around implants.
Information sources and literature search
Electronic search was performed on three sources (last search
December 31, 2015; no date restriction used): Medline
(PubMed), Embase (Ovid), and CENTRAL (Ovid). The data-
base Medline (PubMed) was searched with the following
keywords: (acellular dermal matrix OR dermal matrix allo-
graft OR alloderm OR soft tissue graft OR free gingival graft
OR human fibroblast-derived dermal substitute OR
dermagraft OR apligraf OR collagen matrix OR extracellular
membrane OR gingival autograft OR soft tissue augmentation
OR soft tissue transplantation OR soft tissue correction) AND
(keratinized tissue OR keratinized gingiva OR attached gingi-
va OR attachedmucosa OR keratinizedmucosa). For the other
two databases, comparable terms were used but modified to be
suitable for specific criteria of the particular database.
Additionally, grey literature (conference abstracts and www.
opengrey.eu) was browsed and a “manual search” through the
electronically available material of the following relevant
journals, including publications ahead of print, was
performed: Journal of Clinical Periodontology, Journal of
Periodontology, Journal of Periodontal Research, Clinical
Oral Investigations, Journal of Dental Research, and
Parodontologie. Screening of the reference lists of previous
reviews and selected full texts was also conducted. Finally, a
forward search via Science Citation Index of included papers
was added and ClinicalTrials.gov was checked on
unpublished or ongoing studies.
Data collection and extraction
Two authors (KB, MM) independently checked titles, ab-
stracts, and finally full texts with regard to the predefined
eligibility criteria. Abstracts with unclear methodology were
included in full-text assessment to avoid exclusion of poten-
tially relevant articles. One author (KB) repeated the literature
search. In case of ambiguity, consensus through discussion
was achieved together with a third author (AS).
Two authors (KB, MM) extracted twice the following data
(if reported): width of KT at baseline and after 3, 6, and
12 months and/or KT gain, difference in KT gain, and graft
contraction; frequency of postintervention width of KT
≥2 mm; and aesthetic (i.e., tissue color and texture) and
PROMs (i.e., postoperative pain level and patient prefer-
ence/satisfaction).
Risk of bias assessment
Two authors (MM,MMK) independently evaluated the risk of
bias applying the Cochrane Collaboration’s Tool for assessing
risk of bias (Cochrane Handbook for Systematic Reviews of
Interventions) [7]. The following domains were evaluated at
“low,” “high,” or “unclear” risk of bias: (a) random sequence
generation, (b) allocation concealment, (c) blinding of out-
come assessment, (d) incomplete outcome data, (e) selective
reporting, and (f) other bias. As the specific research question
(comparison of an autologous palatal tissue graft with a STS)
makes it impossible to blind the personnel during surgery and
almost impossible to blind the patients, the criterion “blinding
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of participants and personnel,” originally included in the tool,
was excluded herein. The overall risk of bias for an individual
study was judged as follows: low, if all criteria were evaluated
to be of low risk; high if at least one criterion was evaluated to
be of high risk; and unclear, if at least one criterion was eval-
uated to be of unclear risk but no criterion of high risk. One
author (MM) repeated the assessment, and in case of ambigu-
ity, consensus through discussion was achieved.
Synthesis of results
The postintervention mean difference between STS and au-
togenous palatal soft tissue graft groups, regarding gain in KT
width (primary outcome variable) and several secondary var-
iables [graft contraction, aesthetic outcome (i.e., tissue color
and texture match to the neighboring tissue), and PROMs (i.e.,
pain level and preference/satisfaction)], was assessed bymeta-
analysis.
Clinical heterogeneity of included studies was gauged by
assessing the treatment protocol, particularly participants and
setting, materials used, timing of data collection, and measure-
ment techniques. Statistical heterogeneity was assessed by
graphic display and consistency of the estimated treatment
effects from the included trials in conjunction with 95% con-
fidence intervals (CIs). The chi-squared test was used to assess
heterogeneity; a p value <0.1 would be considered indicative
of significant heterogeneity [8]. I2 test for homogeneity was
also undertaken, where possible, to quantify the extent of het-
erogeneity prior to each meta-analysis.
Quantitative synthesis was performed using the
DerSimonian and Laird random effect methods [9] for all
included studies and separately for comparing “acellular graft
substitutes vs. FGG” and “tissue-engineered graft substitutes
vs. FGG.” Aweighted mean pooled treatment effect was cal-
culated with 95% CIs for the continuous outcome variables
using a random effects model; a random effects model was
considered more appropriate in view of the variation in popu-
lation and settings. Pooled estimates were also calculated sep-
arately per follow-up period (i.e., 3, 6, and 12 months). Most
comparisons (9/11) were derived from split-mouth studies,
and in those instances where the standard deviation of the
mean difference was not available, it was calculated using
the formula
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
sd treat2 þ sd control2−2*r*sd treat*sd control
p
where sd_treat and sd_control are the corresponding stan-
dard deviations and r is the correlation coefficient for the
between treatment group measurements. The correlation coef-
ficient was set at 0.5; however, syntheses were also conducted
using values of r = 0 in the context of sensitivity analyses. For
binary outcomes (i.e., aesthetic outcome and PROMs), a sim-
ilar adjustment was implemented using r = 0.5 to calculate the
variances on a logarithmic scale, before conversion to the
exponentiated form.
Results
Study selection
The flowchart of the literature search is presented in Appendix
2. Out of 485 originally identified studies, 314 and 139 were
excluded based on title and abstract, respectively. Seven addi-
tional records were retrieved from reference lists of previous
reviews and selected full-text articles, and two were identified
from the forward search. No unpublished or ongoing studies
were identified. From the 41 articles selected for full-text re-
view, 33 [References of excluded studies, 1-33] were excluded
for various reasons (for details, see Appendix 3). Finally, eight
clinical trials [10–17] were included; further on, the studies will
be cited with Roman numbers as indicated in Table 1.
Study characteristics
Study populations
Sample size ranged from 5 to 96 patients; two studies (VI,
VIII) excluded from the analysis some patients, which had
initially been treated for training purposes. All studies report-
ed patient age range, but one (III) reported mean age. Sex
distribution was reported in seven studies (I–III, V–VIII).
Smoking status was not reported in three studies (II–IV); four
studies (V–VIII) included non-smokers and former smokers
and one (I) only non-smokers (Table 1).
Type of intervention
Indication for treatment in all included studies was an insuffi-
cient zone of KT [two studies (II, V)] or of AG [six studies (I,
III, IV, VI–VIII)]. All studies were RCTs [6 with split-mouth
design (III–VIII)] and comparisons regarded “STSs and APF”
vs. “FGG and APF.” The follow-up period ranged from 3 to
12 months. All studies reported no patient loss to follow-up
(Table 1).
Type of autogenous soft tissue grafts and STSs
All studies used FGG as the main control group, while one
study (II) included a second control group with subepithelial
CTG. The apico-coronal graft dimension in the control group
was either predefined to 4–5mm (V–VIII) or measured during
grafting (I).
Five different STSs were tested: three acellular matrices
[AlloDerm® (I, II); DynaMatrix® (III); Mucograft® (IV,
V)] and two tissue-engineered STSs [CelTx™ (VII, VIII);
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Dermagraft® (VI)] (Table 2). The apico-coronal dimension of
the STS was either predefined (5 mm) (VI, VII) or measured
during grafting (I, VIII). Four studies (I, II, IV, V) used the
STS in a single layer and two studies (VII, VIII) in three
layers, and two studies (III, VI) tested various numbers of
layers (Table 1). In seven studies (I–VII) no remarkable ad-
verse events (AE) were reported. One study (VIII) included a
detailed AE report: in two patients, the polycarbonate mem-
brane on which CelTx™ is supplied was unintentionally used;
a third patient showed a mouth ulceration; another three seri-
ous AE (e.g., pneumonia, chest pain) were considered unre-
lated to the intervention. Currently, Dermagraft® is not avail-
able in the market and CelTx™ is not distributed for dental
use (Table 2).
Type of reported outcome variables
Apart from KT width, only two studies (I, VI) assessed graft
contraction quantitatively (Table 3). Regarding PROMs, most
studies performed a qualitative assessment; e.g., only three
studies (V, VI, VIII) evaluated specifically tissue color and
texture after treatment by scoring clinical photographs or di-
rect clinical examination using calibrated examiners, while in
five studies (I–IV, VII), only a description by the authors was
given (Table 4). Similarly, the pain associated with the inter-
vention (II, III, VI–VIII) or patient preference regarding the
intervention (IV–VIII) was assessed by simply asking the pa-
tients (Table 5).
Results on KTwidth
Five studies [RoB: low (VII); unclear (I); high (II–IV)] pre-
sented a significant increase in KTwidth from baseline to final
evaluation values (i.e., comparison “A” in Table 3). In the STS
and FGG groups, the increase in KT width ranged from 1.26
to 4.1 mm and from 2.57 to 5.57 mm, respectively. Five stud-
ies [RoB: low (V, VII, VIII); unclear (I); high (VI)] found
significantly wider KT in the FGG group at final evaluation
(i.e., comparison “B” in Table 3). Six studies compared gain in
KT width between the groups (i.e., comparison “C” in
Table 3); four studies [RoB: low (V, VII), unclear (I); high
(III)] showed significantly larger gain in the FGG group.
Regarding presence of ≥2 mm KT after treatment, three stud-
ies [RoB: low (VII); high (II, III)] reported a frequency of
100% for FGG, four studies [RoB: low (V, VII, VIII); high
(III)] reported a frequency of 76–100% for STSs, and one
study [high RoB (II)] reported a range of 1.5–8.5 mm KT
width, i.e., <100% frequency, for STS. Graft contraction was
reported in two studies [RoB: unclear (I); high (VI)] (Table 3)
and was significantly higher (2 and 4.4 times, respectively) in
the STS group.
Results on PROMs
In all studies, but one (II), significantly better color and texture
match of the grafted region with the neighboring tissues was
reported for the STS group compared to the FGG group, both
when judged by the patients [RoB: low (V, VIII)); high (VI)]
or the authors [RoB: low (VII); unclear (I); high (III, IV)]. In
general, color and texture match was achieved in about 90%
of the cases in the STS group, while the tissue color was less
red and the texture was less firm in the grafted area in >70 and
>45% of the cases, respectively, in the FGG group (Table 4).
In the last study [high RoB (II)], the authors judged the ap-
pearance of the STS also as patch like, similarly to the FGG
group.
No significant difference between STS and FGG regarding
the level of pain experienced by the patient was reported in
two studies [RoB: low (VIII); high (VI)]; however, one (VI) of
the studies assessed pain only after 3 months postoperatively.
In all studies, but one [high RoB (VI)], a significant difference
in favor of the STS (range 60–76.5%) regarding patient pref-
erence was reported [low RoB (V, VII, VIII)] (Table 5).
Synthesis of results
KTwidth
Pooled comparisons (Fig. 1a) Regarding the comparison be-
tween any kind of STS and FGG, the overall pooled estimate
(i.e., not considering the time point of comparison) was
−1.55 mm favoring FGG (p < 0.001), but with significant
heterogeneity. In the sensitivity analysis where r was set at
an extreme r = 0, overall pooled estimate remained significant
in favor of FGG with −1.55 mm (95% CIs −1.90, −1.20,
p < 0.001). The predictive intervals for the overall pooled
estimate indicated that the KT width achieved with STS in a
future trial is likely to be −2.57 to −0.54 mm less than what
would be achieved with FGG.
Comparisons between FGG and acellular matrices
(Fig. 1b) For comparison between FGG and acellular matri-
ces, the overall pooled estimate was −1.64 mm favoring FGG
(p < 0.001), but with significant heterogeneity. In the sensitiv-
ity analysis where rwas set at an extreme r = 0, overall pooled
estimate remained significant with −1.61mm (95%CIs −2.33,
−0.90, p < 0.001).
Comparisons between FGG and tissue-engineered STSs
(Fig. 1c) For comparison between FGG and tissue-
engineered STSs, the overall pooled estimate was −1.48 mm
favoring FGG (p < 0.001), but heterogeneity was significant.
In the sensitivity analysis where r was set at an extreme r = 0,
overall pooled estimate remained significant with −1.48 mm
(95% CIs −1.83, −1.12, p < 0.001).
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Graft contraction
Since the last review [3], no new data were available on the
parameter “graft contraction.” There, it was reported that STSs
showed significantly larger (28.4% on average) contraction
compared to that observed in FGG.
Tissue color and texture match (Fig. 2a, b)
The overall pooled estimate of the OR for tissue color match
in the grafted region with the neighboring tissue was 37.84
favoring STSs (p < 0.001); heterogeneity was low. Similar, the
overall pooled estimate of the OR for tissue texture match was
70.12 again favoring STSs (p < 0.001); heterogeneity was
significant.
Patient preference (Fig. 2c)
The overall pooled estimate of the ORwas 8.74 favoring STSs
(p < 0.001); heterogeneity was low.
RoB assessment
Since less than ten studies were included in the meta-analysis,
standard funnel plots and contour-enhanced funnel plots [18]
were not possible to use to examine publication bias. Three
studies (V, VII, VIII) were assessed as of low, one study (I) of
unclear, and four studies (II, III, IV, VI) of high RoB. RoB
analysis of each of the included studies and overall risk are
presented in Appendixes 4 and 5. Further, four studies (I, II,
III, IV) were described by the authors as RCTs, but the ran-
domization process was not defined. Reasons for assigning
“other bias” to the various studies are also included in
Appendix 4.
Discussion
The results of the present systematic review indicate that, on
the basis of relatively limited clinical evidence, the use of a
STS is inferior than the use of a FGG harvested from the palate
in increasing the width of KT in non-root coverage proce-
dures, when combined with APF. However, better color and
texture match of the grafted area with the neighboring tissues
is consistently observed with STSs.
The necessity or not to have a minimum amount of AG in
order to sustain periodontal health has been debated in the past
[19–26]. In particular, based on the observation made in a clin-
ical study that despite daily (professionally delivered) prophy-
laxis, plaque-free tooth surfaces with <2 mm of KT continued
to exhibit clinical signs of inflammation, it was widely sug-
gested that ≥2 mm KT is a requirement for periodontal tissue
stability [21]. In other clinical studies, however, patients with
limited amount of KT (even with <1 mm) did not experience
Table 2 Characteristics of the tested STSs
Product name Origin of the material Company Product sold in Adverse events
Acellular matrices
AlloDerm® Human freeze-dried, cell-free,
dermal matrix
LifeCell Corp., Branchburg, NJ,
USA
USA, distributed in the EU via
HTA
None
DynaMatri-
x®
Porcine small intestinal
submucosa
(collagens,
glycosaminoglycans,
glycoproteins, proteoglycans,
growth factors)
Keystone Dental, Turnpike
Burlington, MA, USA
USA and Europe since 2008 None
Mucograft® Porcine bilayer collagen matrix Geistlich Pharma, Wolhusen,
Switzerland
USA and EMEA since 2010 None
Tissue engineered
CelTx™
(Apligraf®)
Living cellular construct
composed of human
fibroblasts, keratinocytes, and
extracellular
matrix proteins on type I
bovine collagen
Organogenesis, Canton, MA, USA FDA approved, but not
distributed for dental use
24 patients reported >1
adverse event
(total of 43 events, no
event
reported by >2
patients); 3 patients
reported adverse
events at LCC site
(McGuire et al. 2011)
[13]
Dermagraft® Living human fibroblast-derived
dermal substitute
Advanced Tissue Sciences, Inc.,
La Jolla, CA, USA
Withdrawn from the market None
FDA Food and Drug Administration, HTA Human Tissue Authority, EMEA Europe, Middle East, Africa
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any attachment loss over a longer period of time [19, 22]. In
context, in a systematic evaluation employing a preclinical
in vivo model [25, 26], it was demonstrated that periodontal
tissues can be maintained clinically and histologically inflam-
mation free, irrespective of the presence or absence of a wide
zone of KT, provided that effective plaque control is performed;
Table 3 Values of the width of keratinized tissue (mm) at baseline and final evaluation, postintervention gain (mm), mean difference in gain (mm)
between test and control groups, graft contraction (%), and frequency of postintervention KT width ≥2 mm (%)
Study (year) Group Baseline (mm) Final evaluation Graft
contraction
(%)
Frequency of
postintervention
KTwidth ≥2 mm
(range or 95% CI
of
postintervention
KTwidth)
Values (mm) Gain (mm) Mean
difference in
gain (mm)
Comparison
based on
Acellular matrices
Wei et al.
(2000) [17]
Test 0.68 ± 0.26a 3.25 ± 0.89a 2.59 ± 0.92a 2.98c A, B, C 71 ± 10a NR
Control 0.57 ± 0.41a 6.15 ± 0.49a 5.57 ± 0.44a 16 ± 12a NR
Harris (2001)
[10]
Test 0.6 ± 0.87a 4.7 ± 1.92a 4.1 ± 1.79a A, C NR <100% (range
1.5–8.5 mm)
Control
(FGG)
0.8 ± 0.59a 4.8 ± 1.16a 4.1 ± 1.25a 0.00c 100% (range
3.0–6.5 mm)
Control
(CTG)
0.4 ± 0.47a 4.0 ± 0.99a 3.6 ± 0.82a 0.50c 100% (range
2.5–5.5 mm)
Nevins et al.
(2010) [15]
Test 0.8 ± 0.7a 3.4 ± 0.8a 2.6 ± 1.1a 2.7c A, C NR 100% (range
2.5–5.0 mm)
Control 1.1 ± 1.1a 6.4 ± 0.9a 5.3 ± 1.3a 100% (range
5.0–8.0 mm)
Nevins et al.
(2011) [16]
Test NR NR 2.3 ± 1.1a 0.80c A, C NR NR
Control NR NR 3.1 ± 0.6a NR
McGuire &
Scheyer
(2014) [14]
Test 0.88 ± 0.61a 2.92 ± 0.88a 2.04c 1.61c B, C NR 96.67% (95% CI
2.59–3.25 m-
m)
Control 0.77 ± 0.68a 4.42 ± 0.64a 3.65c NR (95% CI
4.18–4.66 m-
m)
Tissue engineered
McGuire &
Nunn (2005)
[11]
Test 1.46 ± 0.91a 2.72
(2.42–3.03)b
1.26c 1.31c B 45.5
(39.5–51.4)b
NR (95% CI
2.42–3.03 m-
m)
Control 1.34 ± 0.97a 3.91
(3.61–4.22)b
2.57c 21.8
(15.9–27.7)b
NR (95% CI
3.61–4.22 m-
m)
McGuire et al.
(2008) [12]
Test 1.07
(0.89–1.25)b
2.40
(2.08–2.72)b
1.33
(0.95–1.71)b
1.96c A, B, C NR 76% (95% CI
2.08–2.72 m-
m)
Control 1.17
(0.99–1.35)b
4.46
(4.14–4.78)b
3.29
(2.91–3.68)b
100% (95% CI
4.14–4.78 m-
m)
McGuire et al.
(2011) [13]
Test 1.41 ± 0.72a 3.21 ± 1.14a 1.80c 1.34c B NR 95.3% (NR)
Control 1.43 ± 0.69a 4.57 ± 1.00a 3.14c NR
Italic values indicate significant difference (p < 0.05)
CTG connective tissue graft, FGG free gingival graft, KT keratinized tissue, NR not reported, SD standard deviation, A comparisons between baseline
and final evaluation values, B comparisons between groups regarded values of KTwidth at the final evaluation, C comparisons between groups regarded
values of KT width gain
aMean (±SD)
bMean (95% CI)
cMean (calculation based on the presented data)
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in contrast, in the presence of plaque, inflammation is clinically
(but not histologically) more pronounced at sites with a narrow
zone of KT, compared to sites with wide and firm AG.
Nevertheless, it has also been reported that, in patients failing
to attend supportive periodontal treatment on a regular basis,
sites with a narrow zone of KTwidth (i.e., 1.4 mm on average)
presented with an increased gingival index and lost attachment
over a period of 6 years, although of questionable clinical mag-
nitude (i.e., 0.5 mm); in contrast, contralateral sites previously
augmented and presenting a wide zone of KT did not show any
deterioration of their periodontal conditions [27]. Altogether,
surgical augmentation of the width of KT in non-root
coverage procedures has nowadays rather limited indications;
as already mentioned, it was suggested in a recent consensus
conference that only in patients where plaque control is inade-
quate and/or submarginal restoration margins are necessary,
soft tissue augmentation procedures should be considered for
sites lacking 2 mmKTwidth (for review, see Scheyer et al. [2]).
Although the use of FGG in combination with APF has
been proven to be a predictable technique for increasing KT
width on the long term [28, 29], the drawbacks associatedwith
the procedure (i.e., second surgical site; limited supply; surgi-
cal complications; often unsatisfactory aesthetic outcome)
have generated the pursuit of STSs. Indeed, various types of
STSs have been proposed and evaluated in the clinic; these
include allogeneic and xenogeneic collagen-based matrices
(AlloDerm®, DynaMatrix®, Mucograft®) and tissue-
engineered constructs including allogeneic cells seeded in xe-
nogeneic matrices (CelTx™, Dermagraft®). The rationale of
using tissue-engineered STSs is that the transplanted cells,
which are not supposed to survive at the recipient site, provide
a superior wound healing environment by secreting various
anti-inflammatory cytokines and growth factors, including
pro-angiogenic factors [30–33]. The results of the present
meta-analysis revealed that use of a STS results in about
1.1–2.2 mm less KT width increase compared to the use of a
FGG. Further, use of a tissue-engineered STS was apparently
not superior to the use of an acellular matrix. Specifically,
average KT gain after the use of tissue-engineered STSs was
never >2mm [11–13], while it ranged between 2.0 and 4.1 mm
after the use of acellular matrices [10, 14–17]. This
underperformance of STS compared to FGG is also depicted
by the significantly larger (by 28%) contraction of STS com-
pared to that of FGG [3]. The results herein indicated also that
the use of an STS does not predictably result in a KT width
≥2 mm after treatment. Only in one [15] out of four reporting
studies, 100% of the sites treated with STS showed ≥2 mm of
KT, while in all three reporting studies, 100% of the sites
Table 4 Tissue color and texture
in STS and FGG groups at final
evaluation
Study (year) Group Tissue color Tissue texture
Less Equally More Less Equally More
Red (%) Firm (%)
McGuire & Nunn (2005)a [11] STS 9.1 90.9 0.0 9.1 90.9 0.0
FGG 68.2 27.3 4.6 77.3 22.7 0.0
McGuire et al. (2011)b [13] STS 2.4 92.9 4.7 0.0 95.3 4.7
FGG 72.9 27.1 0.0 45.9 54.1 0.0
Match to neighboring tissue (%)
McGuire & Scheyer (2014) [14] STS 87 97
FGG 10 0
Authors’ description of the STS groupc
Wei et al. (2000) [17] “Appears similar to the
alveolar mucosa”
“Appears similar to the alveolar
mucosa”
Harris et al. (2001) [10] NR “CTG and AD seemed to produce a
more aesthetic result in most
cases; however, both produced a
result that was as ‘patch like’ in
appearance as a FGG”
McGuire et al. (2008) [12] “Significant better
matching”
“Significant better matching”
Nevins et al. (2010) [15] “Excellent color blend” “Excellent texture blend”
Nevins et al. (2011) [16] “Excellent color blend” “Excellent texture blend”
Italic values indicate significant difference between the test and control groups (p < 0.05)
AD Alloderm®, CTG connective tissue graft, FGG free gingival graft, NR not reported
a Recorded 12 months after treatment
b Recorded 6 months after treatment
c Data and evaluation parameters are not presented
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treated with FGG had ≥2 mm KTwidth [10, 15]. In perspec-
tive, despite the fact that the rationale for performing an aug-
mentation procedure is to achieve KTwidth ≥2 mm, only half
of all included studies reported on the frequency of this
outcome.
On the other hand, all but one [10] of the included studies
revealed that better tissue color and texture match of the
grafted site with the neighboring tissue was achieved with
the use of a STS compared to that of a FGG [11–17].
Specifically, color and texture match was achieved in about
90% of the cases treated with a STS, while color and texture
mismatch occurred in >70 and >45%, respectively, of the
cases treated with a FGG. This finding of poor tissue color
and texture match after the use of FGG is by far not surprising,
since it is for long known that FGG preserves the histological
characteristics of the donor site after transplantation [34].
Similarly, most studies reporting on patient preference de-
scribed a significant difference in favor of the use of STS
[12–14], while only one study [11] described no difference.
Indeed, no remarkable adverse reactions were observed, thus
raising no safety concerns for the use of STS. It seems
reasonable to assume that patients favored STS due to less
discomfort and/or pain compared to the use of a FGG.
Nevertheless, in the two studies [11, 13], where pain was
assessed using a validated instrument, no difference was re-
corded between the treatment groups. It has, however, to be
mentioned that the use of a split-mouth design (as several
studies herein [11–14]) may bring bias in pain assessment
[35–37]. Again, it is interesting to note that despite the fact
that less discomfort and/or pain and better aesthetic results are
among the incentives to use STS instead of a FGG, these
parameters were systematically and/or properly evaluated on-
ly in a fraction of the included studies.
In addition, limited standardization and large variability
were observed among the studies regarding various factors
related to the surgical procedure, e.g., the size of the recipient
bed and/or application of single or multiple STS layers, which
appear to influence the outcome and might be responsible for
the significant heterogeneity that was frequently observed.
Particularly, improved results in KT width gain have been
reported with increased mesio-distal graft dimension [12]
(i.e., treatment of multiple teeth) and the use of a multi-layer
Table 5 Patient-reported outcome measures on pain level and preference/satisfaction
Study (year) Group Pain level Patient preference/satisfaction
None (%) Mild (%) Moderate (%) Severe (%)
McGuire & Nunn (2005)a [11] STS 13.6 50.0 31.8 4.6 9.91 ± 1.54b
FGG 13.6 54.6 27.3 4.6 10.20 ± 1.13b
After 3 days (%) After 7 days (%)
McGuire et al. (2011)c [13] STS 70.6 45.9 76.5%
FGG 62.3 37.7 23.5%
Authors’ descriptiond
Harris (2001) [10] STS “Higher pain levels in the FGG group from the donor site... These
patients tended to take more pain medication and for a longer
period of time.”
NR
FGG
CTG
McGuire et al. (2008) [12] STS “Subject perception of the duration of pain was reduced in the
STS sites.”
60%
FGG 20% (no preference 20%)
Nevins et al. (2010) [15] STS “Patients reported less discomfort related to the palatal harvest
with the DynaMatrix when compared to the autogenous sites.”
NR
FGG
McGuire & Scheyer (2014) [14] STS NR 70%
FGG 30%
Nevins et al. (2011) [16] STS NR Authors’ descriptiond
FGG “Significant bias toward avoiding palatal
harvesting, in favor of the STS group”
Wei et al. (2000) [17] STS NR NR
FGG
Italic values indicate significant difference between STS and FGG groups (p < 0.05)
CTG connective tissue graft, FGG free gingival graft, NR not reported, SD standard deviation
a Pain level at 3 months after treatment (=first evaluation time point)
bMean (±SD) of a specific not clearly defined scale
c Pain at recipient site
d Data and evaluation parameters are not presented
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Fig. 1 a–c Forest plot on the
effect size of treatment after
application of a FGG (=control)
compared to a all tested graft
substitutes, b an acellular matrix,
or c a tissue-engineered STS
(=treatment) overall and after 3, 6,
and 12 months
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technique [11]. Thus, comparisons among studies, regarding
the performance of the different STSs, have to be done with
caution. Furthermore, when judging the currently available
evidence on the topic, one has to take into account that only
three of the included studies [12–14] where judged as of low
RoB. It is thus reasonable to require that future studies con-
sistently and systematically follow the CONSORT guidelines
for reporting of RCTs [38] and evaluate and report on the
possible effect of anatomical and surgical factors (e.g., size
of the recipient bed and vestibulum depth; treatment of single
Fig. 2 a–c Forest plot on the
tissue a color and b texture match
and c patient preference after
application of a FGG (=control)
compared to a STS (=treatment)
Clin Oral Invest (2017) 21:505–518 515
or multiple sites; application of single or multiple layers) and
on relevant treatment outcomes (i.e., frequency of ≥2 mm KT
width postoperatively; PROMs).
In summary, the present systematic review and meta-
analyses reached basically to similar conclusions as previous
systematic reviews [3, 39] on with this topic:
– No preclinical in vivo studies comparing autogenous soft
tissue grafts with a STS material are available.
– Use of STSs (acellular matrix or tissue engineered) in com-
bination with APF resulted in a significantly less gain of KT
width compared to what achieved with FGG and APF.
– Use of a tissue-engineered STS was apparently not supe-
rior to the use of an acellular matrix.
– Use of STS does not predictably result in a KT width
≥2 mm after treatment, while use of FGG does.
– Significantly better aesthetic outcomes and larger patient
preference in favor of STS were observed.
– STS materials appeared to be safe.
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